Wegovy 3 month results: what most people see at 12 weeks

What do the trial data actually show at around 12 weeks?

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight for 68 weeks. Interim data and published graphs show that by around week 12, participants on semaglutide 2.4mg had shed roughly 5–8% of their baseline weight on average. That sounds modest compared with the headline 15% figure, but the headline is a 68-week result, and three months is not even halfway through the titration schedule.

The weight curve in STEP 1 was not flat after week 12. Loss accelerated once people reached the full 2.4mg maintenance dose, which most patients hit at or after month four. So the three-month result is a genuine early signal, not a preview of your ceiling. People who had lost less than 5% by week 12 were not necessarily heading for poor outcomes, individual pace varies with starting weight, diet, activity and how quickly the dose was increased.

One pattern is consistent across the data: appetite suppression tends to be firmly established by month three even if the scale hasn't moved as fast as expected. Many people describe month three as the point where food noise quietens down noticeably. That shift in appetite is often the groundwork for the larger losses that follow, and you can read more about what to expect next on the Wegovy 4 month results page.

Why does the dose you're on at three months matter so much for your results?

At three months, most people are somewhere between 1.0mg and 1.7mg per week, not yet at the 2.4mg maintenance dose. The prescriber titrates roughly every four weeks, adjusting if side effects require a slower pace. That means results at 12 weeks partly reflect a medicine that hasn't yet reached its full working dose.

This is worth sitting with if your three-month results feel disappointing. A useful parallel from the Wegovy overview: the early doses are calibration, not therapy at full strength. Once 2.4mg is established and tolerated, the rate of loss typically picks up. The MHRA-approved single-dose 7.2mg pen, approved in April 2026, offers a higher maintenance option for eligible patients, though that's a clinical conversation for much later in treatment.

Dose pace also explains why results vary so much between individuals at this milestone. Someone who tolerated each increase well and reached 1.7mg by week 12 will likely show more loss than someone who paused at 0.5mg for an extra month because of nausea. Neither outcome means the medicine isn't working. It means titration is personal.

If you're trying to understand how results build from here, the six-month Wegovy results page covers what the data show once maintenance dose is established.

What shapes how much weight you lose in the first three months?

Several factors influence where you land at 12 weeks. Starting BMI plays a role: people with higher starting weights often see larger absolute losses early on, even if the percentage is similar. Activity level and dietary changes matter too, the STEP 1 trial included lifestyle support alongside the medicine, and the NHS notes that Wegovy works alongside a reduced-calorie diet and increased physical activity, not instead of them. The NHS England guidance on weight-management injections sets out what that wraparound care looks like in practice.

Timing of your injections is another practical factor. People who inject consistently on the same day each week, store their pens correctly in the fridge, and follow the prescriber's guidance on missed doses tend to get more consistent results. Worth noting: if you started treatment around a holiday period or had a few weeks of disrupted routine, three months may not reflect a full 12 weeks of steady treatment, something to flag with your prescriber rather than read as a failure.

Genetics and individual response to semaglutide also play a part that no one can fully predict before starting. Some people are fast responders; others see the bulk of their progress from month four onwards. Both patterns appear in the trial data. For a broader read on how quickly the medicine typically begins to work, the page on how long Wegovy takes to work covers the mechanisms in more detail.

Should you be concerned if your three-month results feel slow?

Not automatically. NICE's recommendation for semaglutide (TA875) includes a review point at six months: if less than 5% weight loss has been achieved by then on the maintenance dose, continuing is reconsidered. The six-month marker is the clinical checkpoint, not the three-month one. Three months is too early to draw firm conclusions about whether the medicine is working for you long-term.

That said, some things are worth discussing with your prescriber at this point. Persistent nausea that's stopped you titrating, injection-site issues, or a sense that appetite suppression simply isn't happening are all worth raising rather than waiting. A good prescriber reviews progress and adjusts, not just renews.

If cost is part of your thinking at three months (perhaps you're weighing whether to continue) the UK Wegovy cost page sets out what honest pricing includes and why the cheapest listing often isn't the full picture. At nume, one transparent price covers the clinical review, prescription and next-working-day delivery; no subscription, no auto-renewal, and a prescriber re-reviews every repeat order. If you'd like to talk through whether treatment is right for you, you're welcome to start a free consultation with our clinical team.